ライフサイエンスコーパス: endoscopic

1 The test might be used in practice to assess endoscopic activity in patients with CD.

2 Noninvasive tests to measure endoscopic activity in patients with Crohn's disease (CD

3 The endoscopic activity of inflammation was determined by th

4 accuracy than the other activity markers for endoscopic activity of patients with CD, moderate correl

5 nflammation was determined by the simplified endoscopic activity score for CD (SES-CD).

6 The different degrees of endoscopic activity were correlated with the following i

7 96%) and accurate (78%) for the diagnosis of endoscopic activity.

8 AI is explored in gastroenterology for endoscopic analysis of lesions, in detection of cancer,

9 to identify patients in remission, based on endoscopic analysis, and monitor CD activity based on se

10 Prophylactic anti-TNF therapy reduces both endoscopic and clinical recurrence rates.

11 CTICE ADVICE 13: After complete eradication (endoscopic and histologic) of intestinal metaplasia has

12 n treatment goals from symptomatic relief to endoscopic and histological healing to achieve better lo

13 amilies with HDGC, the growing capability of endoscopic and histological surveillance in HDGC, and in

14 rgy device use if appropriate, and adjusting endoscopic and laparoscopic practice (low CO2 pressures,

15 New endoscopic and less invasive surgical procedures are evo

16 Endoscopic and less invasive surgical techniques are eme

17 ume of available evidence on the benefits of endoscopic and minimally invasive surgical therapies for

18 Endoscopic and pathological findings and clinical events

19 ing their postoperative surveillance through endoscopic and physiological approaches.

20 titis in cases not amenable to less invasive endoscopic and/or surgical procedures.

21 annual hospital caseload, type of procedure (endoscopic), and patients' features (obesity, cardiac hi

22 e activity was determined based on clinical, endoscopic, and histologic criteria.

23 ardiac history (P=0.008), obesity (P=0.048), endoscopic approach (P=0.005), and low-volume center (P<

24 .999), none of the patients assigned to the endoscopic approach developed enteral or pancreatic-cuta

25 inimally invasive surgery using an endonasal endoscopic approach or an anterior endoscopic orbitotomy

26 ed procedure perpetuated the reliance on the endoscopic approach.

27 detection by employing a fluorescence-based endoscopic approach.

28 focused parathyroidectomy by open (88.7%) or endoscopic approach.

29 e effective and reduce the need for repeated endoscopic assessment of disease activity during food re

30 In addition to histologic and endoscopic assessment, esophageal biopsy specimens were

31 s of treatment with propranolol/nadolol plus endoscopic band ligation.

32 lanations for those symptoms, should undergo endoscopic biopsies to determine healing even in the pre

33 the primary tumor site, 12 studies evaluated endoscopic biopsies, 11 qualitative EUS, 14 qualitative

34 ities and specificities were 33% and 95% for endoscopic biopsies, 96% and 8% for qualitative EUS, 74%

35 ponse evaluations included (18)F-FDG PET/CT, endoscopic biopsies, and endoscopic ultrasound with fine

36 Endoscopic biopsies, collected according to center proto

37 literature suggests insufficient accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single

38 o perform a meta-analysis on the accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) for detec

39 til February 2018 for studies on accuracy of endoscopic biopsies, EUS, or PET(-CT) for detecting loco

40 were established from surgical specimens and endoscopic biopsies, expanded in Matrigel, and used for

41 on histologic assessment of dysplasia within endoscopic biopsies.

42 ric cancer is diagnosed histologically after endoscopic biopsy and staged using CT, endoscopic ultras

43 Patients who underwent endoscopic biopsy had decreased operative times and shor

44 aries' of clonogenic cells from 1-mm-diamter endoscopic biopsy samples from the human gastrointestina

45 Using an endoscopic biopsy-based wound healing model, we report t

46 Endoscopic but not clinical remission increased with dos

47 as a risk factor for progression but various endoscopic characteristics were not, suggesting that scr

48 gement, with a limited role for preoperative endoscopic clearance.

49 learning prediction model with validated pre-endoscopic clinical risk scoring systems (the Glasgow-Bl

50 Omalizumab significantly improved endoscopic, clinical, and patient-reported outcomes in s

51 In a randomized trial, we found that endoscopic clip closure of the mucosal defect following

52 ue, ab-interno trabeculectomy dual blade and endoscopic cyclophotocoagulation (ECP) surgeries in pati

53 mulsification, ab-interno trabeculectomy and endoscopic cyclophotocoagulation effectively reduced IOP

54 cal adjuvants in mucosal-sparing, mechanical endoscopic dacryocystorhinostomy (MMED) for primary acqu

55 ectively collected demographic, clinical and endoscopic data as well as information on the recovery p

56 Demographic, clinicopathological, and endoscopic data were collected.

57 The patients' symptoms, and radiological and endoscopic data were pre/postoperatively recorded.

58 Endoscopic decompression is a safe procedure for acute m

59 n real time in clinical practice, to improve endoscopic detection of early neoplasia in patients with

60 Variations in rate of endoscopic detection of serrated polyps indicate the nee

61 e transglutaminase antibodies (tTGA) without endoscopic determination of celiac disease (called celia

62 DJBL is an endoscopic device for treating obesity and related disor

63 ed for the EMR+ procedure, allowing a second endoscopic device to be used through the AWC while using

64 of varices was not strong enough to replace endoscopic diagnosis.

65 l corticosteroids), dietary restriction, and endoscopic dilation.

66 Endoscopic disease activity scoring in ulcerative coliti

67 e EHI identified patients with resolution of endoscopic disease activity, with good overall accuracy,

68 r example, Raman spectroscopy, for assessing endoscopic disease severity according to the four-level

69 Furthermore, assessing endoscopic disease severity is limited by the requiremen

70 VICE 7: Percutaneous drainage and transmural endoscopic drainage are both appropriate first-line, non

71 ould be strongly considered as an adjunct to endoscopic drainage for WON with deep extension into the

72 Patients who underwent biopsy (endoscopic endonasal vs. open craniotomy) for isolated p

73 based lesions in the GI tract using standard endoscopic equipment and a novel AWC device.

74 rough the AWC while using otherwise standard endoscopic equipment.

75 In case of complete endoscopic eradication, the neosquamous mucosa and the g

76 Endoscopic evaluation (performed in 19/48 versus 25/48 p

77 risk factors for celiac disease must undergo endoscopic evaluation after 1-3 years on a gluten-free d

78 extubation, all patients received a flexible endoscopic evaluation of swallowing examination that ent

79 For each flexible endoscopic evaluation of swallowing examination, larynge

80 Endoscopic evaluation of the graft is also important in

81 Endoscopic evaluation was performed in patients with int

82 red patient and graft survival, frequency of endoscopic evaluation, episodes of acute rejection, nutr

83 and randomly selected for independent expert endoscopic evaluation.

84 England on hospital attendances, imaging and endoscopic evaluations, surgical procedures, cancer, and

85 ts (62% male; median age, 58.5 yr) underwent endoscopic examination after extubation.

86 Endoscopic examination of the GI tract is necessary to e

87 After abandoning protocol surveillance, endoscopic examination was decreased significantly at ou

88 venous malformations is often described when endoscopic examinations are performed.

89 Upper and lower GI tract endoscopic examinations found no bleeding.

90 nd 48 healthy subjects during nasopharyngeal endoscopic examinations.

91 on, defined as a composite of major surgery, endoscopic excision of advanced adenomas, diagnosis of h

92 ormed at referral centers with the necessary endoscopic expertise and interventional radiology and su

93 s was determined to be affected by technical endoscopic factors, 17% of PCCRCs by administrative fact

94 Three independent readers scored endoscopic features and a confidence level score for a C

95 RE) and magnetic resonance imaging, specific endoscopic features can be used to select patients for a

96 marker of type 2 inflammation), and abnormal endoscopic features compared with placebo.

97 ibody against IL13) to reduce histologic and endoscopic features compared with placebo.

98 scopy and positive predictive value (PPV) of endoscopic features for a CR were calculated.

99 reflect esophageal dysfunction, and typical endoscopic features include linear furrows, white plaque

100 astric molecular profiles and histologic and endoscopic features, providing insight and clinical read

101 Family history of DGC and endoscopic findings therefore do not appear to be reliab

102 mprovements in histology, eosinophil counts, endoscopic findings, and symptoms.

103 d with esophagitis based on histological and endoscopic findings, including eosinophilic infiltration

104 ristics, presentations, comorbid conditions, endoscopic findings, treatments, and outcomes were compa

105 er gastrointestinal symptoms, histologic and endoscopic findings.

106 ed diagnostic and prognostic significance of endoscopic findings.

107 recurrence is common and mandates continued endoscopic follow-up.

108 Endoscopic food removal was significantly more commonly

109 In these situations, endoscopic full thickness resection (EFTR) with an over-

110 Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes are frequentl

111 available evidence, anti-reflux surgery and endoscopic GERD treatment modalities have no therapeutic

112 MMP9, TGFA, CEACAM1, and VCAM1), called the endoscopic healing index [EHI], using samples from 278 p

113 currently available tools and techniques for endoscopic hemostasis, and be comfortable applying conve

114 Endoscopic hemostatic treatment was administered at init

115 inct endotype defined by more severe atopic, endoscopic, histologic, and transcriptomic features.

116 performed pretraining using 494,364 labeled endoscopic images collected from all intestinal segments

117 ns, utilized both, simulations and annotated endoscopic images, to train deep neural networks at diff

118 Micro-endoscopic imaging of neurons positive for oestrogen rec

119 e recorded hippocampal calcium activity with endoscopic imaging of the genetically encoded fluorophor

120 terval [CI], 2.5 to 15.0; P = 0.006), as was endoscopic improvement (39.7% vs. 27.7%; difference, 11.

121 nts included the proportion of patients with endoscopic improvement (subscores of 1 or less) from bas

122 aintenance therapy than either histologic or endoscopic improvement alone.

123 Histologic improvement and endoscopic improvement following induction were associat

124 Endoscopic improvement occurred in 41.8% of patients rec

125 ect to achievement of clinical remission and endoscopic improvement, but not corticosteroid-free clin

126 this endpoint alone, and in combination with endoscopic improvement, is unknown.

127 ctive than placebo in producing clinical and endoscopic improvements.

128 oscopy was measured with the Crohn's Disease Endoscopic Index of Severity (CDEIS).

129 ic Mayo score (eMS) and 1 Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score.

130 f <=2 and <=1 in each segment, or a total CD endoscopic index of severity score <3) was assessed by u

131 d and distributed according to the degree of endoscopic inflammatory activity into remission, mild ac

132 Endoscopic injection sclerotherapy (EIS) is a life-savin

133 rstand the risk of bleeding from therapeutic endoscopic interventions (eg, endoluminal resection and

134 after a further 10 days with no surgical or endoscopic interventions.

135 Gastrostomy tube placement (surgical or endoscopic) is a generally safe and a reasonable therape

136 Muller matrix polarimeter with potential for endoscopic label-free cancer diagnostics.

137 Endoscopic management of gastroesophageal reflux disease

138 ority of biliary complications resolved with endoscopic management.

139 assigned each full-length endoscopy videos 1 endoscopic Mayo score (eMS) and 1 Ulcerative Colitis End

140 defined as a total Mayo score of <=2 with an endoscopic Mayo score of 1 or less at week 8.

141 ed the validity of a combined histologic and endoscopic (Mayo endoscopy subscore, 0 or 1) improvement

142 is especially challenging, with imaging and endoscopic methods having only modest sensitivity for th

143 improvement endpoint, which we called histo-endoscopic mucosal healing (or histo-endoscopic mucosal

144 week 44, 61% of patients (56/92) with histo-endoscopic mucosal healing after induction therapy achie

145 tekinumab indicated the achievement of histo-endoscopic mucosal healing after induction therapy is as

146 ciated with 10% to 20% higher rates of histo-endoscopic mucosal healing, clinical remission, and cort

147 d histo-endoscopic mucosal healing (or histo-endoscopic mucosal improvement).

148 Endoscopic mucosal resection (EMR) is a minimally invasi

149 of mucosal defects with clips after colonic endoscopic mucosal resection (EMR) prevents delayed blee

150 Patients undergoing endoscopic mucosal resection of nonpedunculated colorect

151 We included peroral endoscopic myotomy (POEM) and gastric peroral endoscopic

152 Peroral endoscopic myotomy (POEM) is a less invasive therapy wit

153 Effect of peroral endoscopic myotomy vs pneumatic dilation on symptom seve

154 ndoscopic myotomy (POEM) and gastric peroral endoscopic myotomy(G-POEM) procedures.

155 Direct endoscopic necrosectomy is a therapeutic option in patie

156 BEST PRACTICE ADVICE 10: The use of direct endoscopic necrosectomy should be reserved for those pat

157 osing metal stents alone, followed by direct endoscopic necrosectomy, and then surgical debridement i

158 Narrow-Band Imaging International Colorectal Endoscopic (NICE) classification system, is used to iden

159 erential collars (r = -0.73, P < .0001), and endoscopic nodularity (r = -0.45, P < .0001).

160 DVICE 6: Hemostatic powders are a noncontact endoscopic option that may be considered in cases of mas

161 and 34% of patients (24/71, P = .0009) with endoscopic or histologic improvement alone after inducti

162 ters and pelvis or for salvage therapy after endoscopic or surgical debridement with residual necrosi

163 in those with WON who are too ill to undergo endoscopic or surgical intervention.

164 antireflux surgery may not decrease risk of endoscopic or surgical re-intervention, suggesting that

165 ng 55 patients (33 female) who had undergone endoscopic or surgical resection of GHPs.

166 endonasal endoscopic approach or an anterior endoscopic orbitotomy over a 5-year period between Janua

167 entional endoscopic sphincterotomy (EST) and endoscopic papillary balloon dilation (EPBD) can be chal

168 Endoscopic placement of intestinal decompression tubes i

169 system, including an imaging console and an endoscopic probe designed to rapidly acquire volumetric

170 se (91% of encounters), performed the fewest endoscopic procedures (12%-17%), but received the highes

171 ral therapies, invasive surgical procedures, endoscopic procedures and lifestyle alterations.

172 However, several failed endoscopic procedures are attributed to incomplete myoto

173 inal obstruction data on the significance of endoscopic procedures for treatment of these conditions

174 Anesthesia services for endoscopic procedures have proliferated with the promise

175 Anesthesia complications among endoscopic procedures in cirrhosis are rare overall.

176 In total, 9,007 endoscopic procedures were performed among patients with

177 sease may warrant more intensive care during endoscopic procedures, including anesthesia monitoring.

178 gnificant added value in guiding surgical or endoscopic procedures.

179 orticosteroids (INCS) significantly improved endoscopic, radiographic, and clinical endpoints and pat

180 tion (adjusted HR = 1.14, 95% CI 0.73-1.77), endoscopic re-intervention (HR = 1.21, 95% CI 0.96-1.51)

181 , the frequencies of 30-day re-intervention, endoscopic re-intervention, and secondary antireflux sur

182 tcomes were 30-day surgical re-intervention, endoscopic re-intervention, and secondary antireflux sur

183 Primary endpoint: endoscopic recurrence (ER) (Rutgeerts score >=i2) after

184 e the only independent predictors of reduced endoscopic recurrence risk.

185 Kono-S) has shown a significant reduction in endoscopic recurrence score and surgical recurrence rate

186 ore by 68.3% (P < .0001 vs placebo), and the endoscopic reference score by 1.6 (P = .0006 vs placebo)

187 scores), endoscopically visualized features (endoscopic reference score), esophageal distensibility,

188 edical record, EoE Histology Scoring System, Endoscopic Reference Score, and EoE Diagnostic Panel ass

189 Based on intent-to-treat analysis, endoscopic remission (SES-CD score <4) was achieved by 3

190 The primary endpoint at week 26 was endoscopic remission (SES-CD score of 4 or less); other

191 oints were clinical remission at week 16 and endoscopic remission at week 12 or 16 using the multiple

192 lled the EHI to identify patients with CD in endoscopic remission based on blood levels of 13 protein

193 al of patients with CD, upadacitinib induced endoscopic remission in a significant proportion of pati

194 Endoscopic remission was achieved by 10% (P < .1 vs plac

195 Preoperative endoscopic removal became the primary method of managing

196 Endoscopic removal of the FCSEMS was achieved in 83.3% (

197 of the Cytosponge from the thread requiring endoscopic removal, and the most common side-effect was

198 We reviewed endoscopic reports of patients referred to our departmen

199 The short-term oncologic efficacy of endoscopic resection (ER) and ablation for patients with

200 of this study was to evaluate the outcome of endoscopic resection (ER) versus esophagectomy in node-n

201 Non-muscle-invasive tumors are treated with endoscopic resection and adjuvant intravesical therapy,

202 l as inconsistencies in risk stratification, endoscopic resection and schedules of delivery of BCG.

203 bleeding (based on Spanish Endoscopy Society Endoscopic Resection Group score).

204 y diversion or trimodal therapy with maximal endoscopic resection, radiosensitizing chemotherapy, and

205 y; visible recurrent nodular lesions require endoscopic resection, whereas flat areas of columnar muc

206 raction and a degree of triangulation during endoscopic resection.

207 e main treatment for early gastric cancer is endoscopic resection.

208 nce of a visible lesion, which should prompt endoscopic resection.

209 core of 4 or less); other endpoints included endoscopic response (50% reduction in SES-CD), radiologi

210 Endoscopic retrograde cholangio-pancreatography (ERCP) i

211 selective biliary cannulation (SBC) and post endoscopic retrograde cholangiography and pancreatograph

212 frequency and severity of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in

213 population-level data on the performance of endoscopic retrograde cholangiopancreatography (ERCP) in

214 apy, early enteral feeding, judicious use of endoscopic retrograde cholangiopancreatography (ERCP), a

215 One of the most feared complications of endoscopic retrograde cholangiopancreatography (ERCP), w

216 Endoscopic retrograde cholangiopancreatography and ballo

217 ted from the bile of PSC patients undergoing endoscopic retrograde cholangiopancreatography earlier i

218 eatitis following abdominal trauma, surgery, endoscopic retrograde cholangiopancreatography, and gall

219 stological analysis from tissue extracted by endoscopic retrograde cholangiopancreatography.

220 aluation and their correlation to the simple endoscopic score (SES-CD) are the goals of this study.

221 following categories: remission with a Mayo endoscopic score = 0 ("deep remission"), remission witho

222 ("deep remission"), remission without a Mayo endoscopic score = 0 ("remission"), or active disease.

223 verall mean GHASs correlated with the simple endoscopic score for CD (r = .6255, P < .0001).

224 s patients in remission (defined as a simple endoscopic score for CD of <=2 and <=1 in each segment,

225 V-EoE had lower endoscopic scores (P < .05).

226 a mean specificity of 93% for the four Mayo endoscopic scores.

227 Guidelines suggest endoscopic screening of individuals who are at increased

228 cur, especially in the second trimester, and endoscopic screening should be recommended.

229 The median number of endoscopic sessions was 4 in patients with short segment

230 Endoscopic severity correlated with esophageal eosinophi

231 , showed significant reductions in validated endoscopic severity score at all esophageal locations (P

232 enteral autonomy and without histological or endoscopic signs of rejection.

233 r use) and objective metrics (pH parameters, endoscopic signs, and lower esophageal sphincter pressur

234 f patients had a history of FESS (functional endoscopic sinus surgery) and reported lower symptom sev

235 e bile duct stones (> 15 mm) by conventional endoscopic sphincterotomy (EST) and endoscopic papillary

236 (P = 0.0001, OR 2.41, 95% CI: 1.05-5.51) and endoscopic sphincterotomy (P = 0.038, OR 2.85, 95% CI: 1

237 A balloon dilation time of 30 s for combined endoscopic sphincterotomy and balloon dilation reduced t

238 oung age, no statin use, history of PEP, and endoscopic sphincterotomy were found to be significantly

239 interventions (eg, endoluminal resection and endoscopic sphincterotomy) and be familiar with the endo

240 on in a high power group patient (treated by endoscopic stenting and normalization after ~4 months) a

241 ncreatic remnant with long-term transenteric endoscopic stenting.

242 work using single-institution databases and endoscopic still images has been promising.

243 mally Invasive Surgery (TAMIS), the other is Endoscopic Submucosal Dissection (ESD).

244 ypectomy, polyp sizes larger than 20 mm, and endoscopic submucosal resection and/or dissection as pol

245 Although the Mayo Clinic endoscopic subscore was not significantly associated wit

246 d-to-moderate UC (modified Mayo scores 4-10, endoscopic subscores >=1).

247 clinical remission (modified Mayo score <=2; endoscopic subscores 0 or 1).

248 al bleeding, and endoscopy findings) of 4-9, endoscopic subscores of 2 or more, and rectal bleeding s

249 l societies (Society of Gastrointestinal and Endoscopic Surgeons, Americas Hepato-Pancreato-Biliary A

250 Current Society of Gastrointestinal and Endoscopic Surgery guidelines recommend CCY over nonoper

251 imentary Tract, and European Association for Endoscopic Surgery).

252 l-sparing approaches or by robotic-assisted, endoscopic surgery.

253 Outcomes of endoscopic surveillance after surgery for colorectal can

254 is increasing confidence from the IGCLC that endoscopic surveillance in expert centres can be safely

255 Helicobacter pylori eradication and endoscopic surveillance of gastric precancerous lesions

256 BEST PRACTICE ADVICE 14: Endoscopic surveillance post therapy should be performed

257 strategy, micronutrient supplementation and endoscopic surveillance.

258 croflora pattern obtained from the uvula and endoscopic swabs did not correlate well with mucosal bio

259 nal preperitoneal patch plasty (TAPP) laparo-endoscopic techniques are recommended for female groin h

260 Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett's oesophagus.

261 hree or larger than 15 mm) received standard endoscopic therapies and UDCA + CBD stenting (group B) a

262 ch of data regarding the reported benefit of endoscopic therapies in GERD.

263 ctice advice statements regarding the use of endoscopic therapies in treating patients with non-varic

264 group B) and controls only received standard endoscopic therapies with only CBD stenting (group A).

265 article is to describe the role of Barrett's endoscopic therapy (BET) in patients with Barrett's esop

266 : 3.57) with decreased survival, compared to endoscopic therapy (P < 0.01).

267 Use of endoscopic therapy for T1 esophageal cancer has increase

268 performed of the initial 40 patients who had endoscopic therapy from 2001 to 2010 at 1 center by 1 ph

269 re recommended, and clips are suggested, for endoscopic therapy in patients with high-risk stigmata.

270 Over a decade, use of endoscopic therapy increased from 12.7% to 33.6%, wherea

271 ization of high-risk ulcers after successful endoscopic therapy is not encouraged.

272 phagogastroduodenoscopy (EGD) or their first endoscopic therapy of early neoplastic BE, from April 20

273 BEST PRACTICE ADVICE 1: Endoscopic therapy should achieve hemostasis in the majo

274 fication in responders and non-responders to endoscopic therapy showed that non-responders had signif

275 Endoscopic therapy through transmural drainage of WON ma

276 hybrid sclerotherapy, one patient underwent endoscopic tissue removal, one patient received percutan

277 ologically and increased in popularity as an endoscopic tool that can provide direct intraductal visu

278 pic sphincterotomy) and be familiar with the endoscopic tools and techniques to treat intraprocedural

279 appear to be superior to plastic stents for endoscopic transmural drainage of necrosis.

280 roach consisting of percutaneous drainage or endoscopic transmural drainage using either plastic sten

281 ed necrosis who do not adequately respond to endoscopic transmural drainage using large-bore, self-ex

282 Endoscopic treatment failed in 17% (17/99) of patients a

283 Endoscopic treatment has a role for specific indications

284 cal treatment is postponed until medical and endoscopic treatment have failed.

285 ts with NVUGIB should undergo endoscopy with endoscopic treatment of sites with active bleeding or hi

286 with invasion of the submucosa that require endoscopic treatment.

287 scribed based on the location and extent and endoscopic treatments offered based on these description

288 ICE ADVICE 7: Magnetic resonance imaging and endoscopic ultrasonography (EUS) should be used in combi

289 subset of patients were selected to undergo endoscopic ultrasonography (EUS) to estimate EI post abl

290 asing facility volume and ability to perform endoscopic ultrasonography were associated inversely wit

291 tibiotic prophylaxis for patients undergoing endoscopic ultrasonography-guided fine needle aspiration

292 Limited data support the utility of endoscopic ultrasound (EUS)/fine needle aspiration (FNA)

293 Endoscopic ultrasound is an increasingly used complement

294 ross-sectional imaging should be used first; endoscopic ultrasound is needed only when CT or MRI are

295 In current guidelines, endoscopic ultrasound with fine-needle aspiration (EUS-F

296 d (18)F-FDG PET/CT, endoscopic biopsies, and endoscopic ultrasound with fine-needle aspiration at reg

297 after endoscopic biopsy and staged using CT, endoscopic ultrasound, PET, and laparoscopy.

298 hrough newer modalities of treatment such as endoscopic ultrasound-guided glue-coiling combination th

299 of hepatocellular carcinoma [HCC] screening, endoscopic varices screening, and use of rifaximin after

300 ive 360-degree surgical approach with a full endoscopic visualization can be safe and efficient in pa